Topic

All

3
Jan
2018

Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA

Spinal muscular atrophy is one of the ongoing success stories in biotech. But that doesn’t mean the story’s over. Cambridge, Mass.-based Biogen won a first-of-its-kind FDA approval a year ago with a new antisense oligonucleotide, licensed from Ionis Pharmaceuticals. The drug, nusinersen (Spinraza), allows kids with a crippling disease to produce greater amounts of the SMN protein they need to...
Read More
3
Jan
2018

Finding a Path in Biotech VC: The Long Run Podcast With Bob More

Today’s guest on The Long Run is Bob More. He’s a managing director with Alta Partners, a healthcare-focused venture capital firm. More got started as a young pup in biotech in the 1980s. He moved around between big companies and small companies. He advanced to a couple well-known healthcare VC firms – Domain Associates and Frazier Healthcare Partners. Before joining...
Read More
21
Dec
2017

How Did BioMarin Make It? The Long Run Podcast With Daniel Levine & Dan Maher

Today on The Long Run, we’re talking about the history of BioMarin Pharmaceutical, one of biotech’s most successful rare disease drug developers. The guests on the show are Daniel Levine and Dan Maher. They are the co-authors of “A Rare Breed: How people and perseverance built BioMarin into one of the world’s most innovative companies.” These two made for a...
Read More
11
Dec
2017

Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?

Grad students are underpaid and underappreciated. Many barely scrape by. Stagnant grant funding for science and uncertain career prospects are the norm. Yet we all know grad students are the mitochrondria of the scientific enterprise. Without them, PIs wouldn’t be looking like geniuses in Nature and Science. Biotech companies wouldn’t have enough of the worker bees they need. Now we...
Read More
29
Nov
2017

The Long Run Podcast: Steve Holtzman on Becoming a Biotech Political Activist

Steve Holtzman is the latest guest on The Long Run podcast. He’s the president and CEO of Boston-based Decibel Therapeutics, a venture-backed startup developing treatments for hearing loss. Holtzman has been a familiar figure around biotech for more than 30 years. He has had leadership roles at Millennium Pharmaceuticals, Infinity Pharmaceuticals, and Biogen. Little known fact: He was a founder...
Read More
27
Nov
2017

Female Contraception, Health and Liberty

[Note: This article was first published on the Leadership and Biotechnology Blog.] Against the backdrop of tax reform, ongoing dialogue around sexual harassment, deepening investigations into the role of Russia in our elections, the crisis in Korea, attempts to dismantle the Affordable Care Act, and continued attempts to restrict immigration and remove Dreamers from the USA, President Trump’s assault on...
Read More